Vitol to Ship First U.S. Naphtha Cargo to Venezuela Under New Oil Supply Deal 
Trump Weighs Blocking Exxon Investment as Venezuela Deemed “Uninvestable” 
SK Hynix Shares Hit Record High as AI Memory Demand Fuels Semiconductor Rally 
Trump Considers Starlink to Restore Internet Access in Iran Amid Protests 
Stellantis to End Plug-In Hybrid Sales in the U.S. as Demand Shifts Toward Traditional Hybrids 
Hanwha Ocean Shares Rise on Plans to Expand U.S. Shipbuilding Capacity 
China’s AI Sector Pushes to Close U.S. Tech Gap Amid Chipmaking Challenges 
Rio Tinto–Glencore Talks Spark Pressure on BHP as Copper Fuels Mining Mega Deals 
Boeing 737 MAX 10 Advances in FAA Testing as Certification Delays Continue 
Elon Musk Says X Will Open-Source Its Algorithm Amid EU Scrutiny 
Nvidia Appoints Former Google Executive Alison Wagonfeld as First Chief Marketing Officer 
Chevron Sees Path to Boost Venezuela Oil Output by 50% After Trump Administration Talks 
FCC Approves Expansion of SpaceX Starlink Network With 7,500 New Satellites 
GM Takes $6 Billion EV Write-Down as Electric Vehicle Demand Slows in the U.S. 
NEW YORK, April 08, 2016 -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of Cardiovascular Systems Inc. securities (NASDAQ:CSII) from September 12, 2011 through January 21, 2016, both dates inclusive (the “Class Period”) of the important April 12, 2016 lead plaintiff deadline in the class action filed by the firm. The lawsuit seeks to recover damages for Cardiovascular Systems investors under the federal securities laws.
To join the Cardiovascular Systems class action, go to the firm’s website at http://rosenlegal.com/cases-738.html or call Phillip Kim, Esq. or Kevin Chan, Esq. toll free at 866-767-3653 or email [email protected] or [email protected] for more information on the class action.
NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. YOU MAY RETAIN COUNSEL OF YOUR CHOICE.
According to the lawsuit, throughout the Class Period Defendants issued false and misleading statements to investors and/or failed to disclose that: (1) Cardiovascular Systems distributed illegal kickbacks to health care providers; (2) Cardiovascular Systems engaged in the off-label promotion of its medical devices; and (3) Cardiovascular Systems violated FDA laws and regulations in connection with its medical devices. As a result of the foregoing, the Company’s public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.
A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than April 12, 2016. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to the firm’s website at http://rosenlegal.com/cases-738.html for more information. You may also contact Phillip Kim, Esq. or Kevin Chan, Esq. of Rosen Law Firm toll free at 866-767-3653 or via email at [email protected] or [email protected].
Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Attorney advertising. Prior results do not guarantee a similar outcome.
Contact Information: Laurence Rosen, Esq. Phillip Kim, Esq. Kevin Chan, Esq. The Rosen Law Firm, P.A. 275 Madison Avenue, 34th Floor New York, NY 10016 Tel: (212) 686-1060 Toll Free: (866) 767-3653 Fax: (212) 202-3827 [email protected] [email protected] [email protected] www.rosenlegal.com
